Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2',3'-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy
Due to a number of unpleasant considerations, marketed drugs have steadily lost their importance in the treatment of cancer. In order to find a viable cancer cell diagnostic agent, we therefore focused on metal complexes that displayed target adequacy, permeability to cancer cells, high standard water solubility, cytoselectivity, and luminescent behavior. In this aspect, luminescent 11-{naphthalen-1-yl} dipyrido [3,2-a:2',3'-c] phenazine based Ru(II)/Ir(III)/Re(I) complexes have been prepared for HCT-116 colorectal cancer stem cell therapy. Our study successfully established the possible cytotoxicity of IrL complex at different doses on HCT-116 colorectal cancer stem cells (CRCSCs). Additionally, an immunochemistry analysis of the complex IrL showed that the molecule was subcellularly localized in the nucleus and other regions of the cytoplasm, where it caused nuclear DNA damage and mitochondrial dysfunction. The level of BAX and Bcl-2 was further quantified by qRT-PCR. The expression of proapoptotic BAX showed increased expression in the complex IrL-treated cell compared to the control, indicating the potential of complex IrL for apoptotic induction. Upon further validation, complex IrL was developed as an inhibitor of autophagy for the eradication of cancer stem cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
ACS applied bio materials - 6(2023), 2 vom: 20. Feb., Seite 410-424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Das, Utpal [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2023 Date Revised 09.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsabm.2c00556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351489932 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351489932 | ||
| 003 | DE-627 | ||
| 005 | 20231226051505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsabm.2c00556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351489932 | ||
| 035 | |a (NLM)36638050 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Das, Utpal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2',3'-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2023 | ||
| 500 | |a Date Revised 09.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Due to a number of unpleasant considerations, marketed drugs have steadily lost their importance in the treatment of cancer. In order to find a viable cancer cell diagnostic agent, we therefore focused on metal complexes that displayed target adequacy, permeability to cancer cells, high standard water solubility, cytoselectivity, and luminescent behavior. In this aspect, luminescent 11-{naphthalen-1-yl} dipyrido [3,2-a:2',3'-c] phenazine based Ru(II)/Ir(III)/Re(I) complexes have been prepared for HCT-116 colorectal cancer stem cell therapy. Our study successfully established the possible cytotoxicity of IrL complex at different doses on HCT-116 colorectal cancer stem cells (CRCSCs). Additionally, an immunochemistry analysis of the complex IrL showed that the molecule was subcellularly localized in the nucleus and other regions of the cytoplasm, where it caused nuclear DNA damage and mitochondrial dysfunction. The level of BAX and Bcl-2 was further quantified by qRT-PCR. The expression of proapoptotic BAX showed increased expression in the complex IrL-treated cell compared to the control, indicating the potential of complex IrL for apoptotic induction. Upon further validation, complex IrL was developed as an inhibitor of autophagy for the eradication of cancer stem cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 1,10-phenanthroline-5,6-dione | |
| 650 | 4 | |a 11-(naphthalen-1-yl)dipyrido[3,2-a:2′,3′-c]phenazine | |
| 650 | 4 | |a DFT analysis | |
| 650 | 4 | |a cell cycle analysis | |
| 650 | 4 | |a dichloro(p-cymene)ruthenium(II) dimer pentamethylcyclopentadienyliridium(III) chloride dimer | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a pentacarbonylchlororhenium(I) | |
| 650 | 7 | |a bcl-2-Associated X Protein |2 NLM | |
| 650 | 7 | |a Coordination Complexes |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Phenazines |2 NLM | |
| 700 | 1 | |a Shanavas, Shanooja |e verfasserin |4 aut | |
| 700 | 1 | |a Nagendra, Apoorva H |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Binoy |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Nilmadhab |e verfasserin |4 aut | |
| 700 | 1 | |a Vardhan, Seshu |e verfasserin |4 aut | |
| 700 | 1 | |a Sahoo, Suban K |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Debashis |e verfasserin |4 aut | |
| 700 | 1 | |a Bose, Bipasha |e verfasserin |4 aut | |
| 700 | 1 | |a Paira, Priyankar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS applied bio materials |d 2018 |g 6(2023), 2 vom: 20. Feb., Seite 410-424 |w (DE-627)NLM287335372 |x 2576-6422 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:2 |g day:20 |g month:02 |g pages:410-424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsabm.2c00556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 2 |b 20 |c 02 |h 410-424 | ||